Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira®) From North American and European Sources in Healthy Adult Subjects
Sponsor: Synermore Biologics Co., Ltd.
Listed as NCT03254810, this PHASE1 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by Synermore Biologics Co., Ltd., it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Synermore Biologics Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .